LP Matrix Capital, a 10% owner, exits entire AURA stake via sale of 6.9M shares.
LP Matrix Capital Management Company, which holds a 10% beneficial stake in Aura Biosciences, has completed a full liquidation of its position by selling approximately 6.9 million shares. This is the fund's second open-market sale in the past three years, following a prior purchase in late 2023 whose outcome remains too recent to evaluate. The stock has appreciated significantly over the past quarter but still trades below its 52-week high, and Aura remains an unprofitable biotech company burning cash with persistent operating losses. The timing coincides with a strong price rally, though without visibility into the fund's specific hold period or acquisition costs, this transaction appears to reflect portfolio rebalancing or capital redeployment by an institutional holder rather than a signal tied to company-specific developments. The complete exit is notable given the fund's substantial ownership size, but the absence of concurrent insider selling by officers or directors limits the ability to draw broader conclusions about management confidence in the business.